NasdaqGM:SUPN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. More Details


Snowflake Analysis

Adequate balance sheet with proven track record.


Similar Companies

Share Price & News

How has Supernus Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SUPN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: SUPN's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

1.6%

SUPN

2.9%

US Pharmaceuticals

0.7%

US Market


1 Year Return

-5.4%

SUPN

7.0%

US Pharmaceuticals

22.2%

US Market

Return vs Industry: SUPN underperformed the US Pharmaceuticals industry which returned 7.4% over the past year.

Return vs Market: SUPN underperformed the US Market which returned 22.7% over the past year.


Shareholder returns

SUPNIndustryMarket
7 Day1.6%2.9%0.7%
30 Day18.0%7.3%11.8%
90 Day-0.4%2.1%8.6%
1 Year-5.4%-5.4%9.7%7.0%25.0%22.2%
3 Year-40.5%-40.5%28.6%19.1%49.4%39.5%
5 Year48.5%48.5%41.4%25.1%100.2%78.1%

Long-Term Price Volatility Vs. Market

How volatile is Supernus Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Supernus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

8.81x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: SUPN ($21.67) is trading above our estimate of fair value ($11.57)

Significantly Below Fair Value: SUPN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SUPN is good value based on its PE Ratio (8.8x) compared to the US Pharmaceuticals industry average (21.8x).

PE vs Market: SUPN is good value based on its PE Ratio (8.8x) compared to the US market (19.4x).


Price to Earnings Growth Ratio

PEG Ratio: SUPN's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: SUPN is good value based on its PB Ratio (1.6x) compared to the US Pharmaceuticals industry average (3.6x).


Next Steps

Future Growth

How is Supernus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-24.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SUPN's earnings are forecast to decline over the next 3 years (-24.8% per year).

Earnings vs Market: SUPN's earnings are forecast to decline over the next 3 years (-24.8% per year).

High Growth Earnings: SUPN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: SUPN's revenue is expected to decline over the next 3 years (-0.5% per year).

High Growth Revenue: SUPN's revenue is forecast to decline over the next 3 years (-0.5% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SUPN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Supernus Pharmaceuticals performed over the past 5 years?

24.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SUPN has high quality earnings.

Growing Profit Margin: SUPN's current net profit margins (27.1%) are higher than last year (26%).


Past Earnings Growth Analysis

Earnings Trend: SUPN's earnings have grown significantly by 24.6% per year over the past 5 years.

Accelerating Growth: SUPN's earnings growth over the past year (22.1%) is below its 5-year average (24.6% per year).

Earnings vs Industry: SUPN earnings growth over the past year (22.1%) exceeded the Pharmaceuticals industry 16.8%.


Return on Equity

High ROE: SUPN's Return on Equity (18.2%) is considered low.


Next Steps

Financial Health

How is Supernus Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: SUPN's short term assets ($552.0M) exceed its short term liabilities ($299.6M).

Long Term Liabilities: SUPN's short term assets ($552.0M) exceed its long term liabilities ($501.5M).


Debt to Equity History and Analysis

Debt Level: SUPN's debt to equity ratio (50.4%) is considered high.

Reducing Debt: SUPN's debt to equity ratio has increased from 7.4% to 50.4% over the past 5 years.

Debt Coverage: SUPN's debt is well covered by operating cash flow (42%).

Interest Coverage: SUPN's interest payments on its debt are well covered by EBIT (40.5x coverage).


Balance Sheet


Next Steps

Dividend

What is Supernus Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SUPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SUPN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SUPN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SUPN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SUPN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.9yrs

Average management tenure


CEO

Jack Khattar (59 yo)

15.92yrs

Tenure

US$8,123,132

Compensation

Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has been its Chief Executive Officer, President, Secretary and Director since 2005. From 1999 to ...


CEO Compensation Analysis

Compensation vs Market: Jack's total compensation ($USD8.12M) is above average for companies of similar size in the US market ($USD2.60M).

Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jack Khattar
Founder15.92yrsUS$8.12m3%
$ 34.7m
Padmanabh Bhatt
Chief Scientific Officer & Senior VP of Intellectual Property8.75yrsUS$1.31m0%
$ 0
Tami Martin
Senior Vice President of Regulatory Affairsno dataUS$874.82k0.16%
$ 1.9m
Stefan K. Schwabe
Chief Medical Officer and Executive VP of Research & Development8.42yrsUS$1.47m0.0053%
$ 60.9k
James Kelly
Executive VP & CFO0.17yrno datano data
Todd Horich
Vice President of Marketing5.92yrsno datano data
Taylor Raiford
Vice President of Sales5.92yrsno datano data
Bryan Roecklein
Vice President of Corporate Development5.42yrsno datano data
Frank Mottola
Senior Vice President of Quality0.92yrno data0.012%
$ 137.2k
Jonathan Rubin
Senior Vice-President of Clinical Research & Medical Affairs0.83yrno datano data

5.9yrs

Average Tenure

59yo

Average Age

Experienced Management: SUPN's management team is seasoned and experienced (5.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jack Khattar
Founder15.92yrsUS$8.12m3%
$ 34.7m
Charles Newhall
Independent Chairman of the Board4.33yrsUS$375.95k0.18%
$ 2.0m
John Siebert
Independent Director9.92yrsUS$357.45k0.11%
$ 1.2m
Georges Gemayel
Independent Director5.75yrsUS$342.45k0%
$ 0
Carrolee Barlow
Independent Director2.5yrsUS$324.95k0%
$ 0
Frederick Hudson
Independent Director10.92yrsUS$359.95k0.024%
$ 282.0k

7.8yrs

Average Tenure

67.5yo

Average Age

Experienced Board: SUPN's board of directors are considered experienced (7.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Supernus Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Supernus Pharmaceuticals, Inc.
  • Ticker: SUPN
  • Exchange: NasdaqGM
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.158b
  • Shares outstanding: 52.69m
  • Website: https://www.supernus.com

Number of Employees


Location

  • Supernus Pharmaceuticals, Inc.
  • 9715 Key West Avenue
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SUPNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2012
S49DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2012
0LB2LSE (London Stock Exchange)YesCommon StockGBUSDMay 2012

Biography

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in th...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/02 23:09
End of Day Share Price2020/12/02 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.